Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans.

[1]  J. Kastelein,et al.  In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1[S] , 2013, Journal of Lipid Research.

[2]  L. Jia,et al.  Ezetimibe Inhibits Hepatic Niemann-Pick C1-Like 1 to Facilitate Macrophage Reverse Cholesterol Transport in Mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[3]  S. Turner,et al.  Measurement of Reverse Cholesterol Transport Pathways in Humans: In Vivo Rates of Free Cholesterol Efflux, Esterification, and Excretion , 2012, Journal of the American Heart Association.

[4]  J. Tomassini,et al.  Intestinal sterol transporters and cholesterol absorption inhibition , 2011, Current opinion in lipidology.

[5]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[6]  J. Xu,et al.  Quantifying cholesterol synthesis in vivo using 2H2O: enabling back-to-back studies in the same subject , 2011, Journal of Lipid Research.

[7]  H. Davis,et al.  Effects of ezetimibe on atherosclerosis in preclinical models. , 2011, Atherosclerosis.

[8]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[9]  J. Kastelein,et al.  Ezetimibe stimulates faecal neutral sterol excretion depending on abcg8 function in mice , 2010, FEBS letters.

[10]  A. Groen,et al.  Transintestinal cholesterol efflux. , 2010, Current opinion in lipidology.

[11]  R. Califf,et al.  An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. , 2010, American heart journal.

[12]  B. Sarkadi,et al.  Model system for the analysis of cell surface expression of human ABCA1 , 2009, BMC Cell Biology.

[13]  Michael Miller,et al.  Extended-release niacin or ezetimibe and carotid intima-media thickness. , 2009, The New England journal of medicine.

[14]  D. Tribble,et al.  Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men , 2009, Journal of Lipid Research.

[15]  D. Rader,et al.  Both the Peroxisome Proliferator‐Activated Receptor δ Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL‐Derived Cholesterol , 2009, Clinical and translational science.

[16]  D. Gómez-Garre,et al.  Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid‐lowering effect , 2009, British journal of pharmacology.

[17]  F. Field,et al.  Origins of intestinal ABCA1-mediated HDL-cholesterol** This work was supported by National Institutes of Health Grant DK-067132. Published, JLR Papers in Press, August 18, 2008. , 2008, Journal of Lipid Research.

[18]  S. Hazen,et al.  Cholesterol Absorption From the Intestine Is a Major Determinant of Reverse Cholesterol Transport From Peripheral Tissue Macrophages , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[19]  D. Rader,et al.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. , 2008, Journal of the American College of Cardiology.

[20]  S. Turley.  The role of Niemann-Pick C1 - Like 1 (NPC1L1) in intestinal sterol absorption. , 2008, Journal of clinical lipidology.

[21]  J. Tomassini,et al.  Ezetimibe : cholesterol lowering & beyond , 2007 .

[22]  Stephen W. Gutkin,et al.  Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe–statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia , 2008, Current medical research and opinion.

[23]  P. Howles,et al.  Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles. , 2007, Biochimica et biophysica acta.

[24]  F. Field,et al.  Ezetimibe interferes with cholesterol trafficking from the plasma membrane to the endoplasmic reticulum in CaCo-2 cells Published, JLR Papers in Press, May 1, 2007. , 2007, Journal of Lipid Research.

[25]  T. V. van Berkel,et al.  Emerging roles of the intestine in control of cholesterol metabolism. , 2006, World journal of gastroenterology.

[26]  T. Starc,et al.  Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. , 2006, Gastroenterology.

[27]  B. Lamarche,et al.  Effect of Ezetimibe on the In Vivo Kinetics of ApoB-48 and ApoB-100 in Men With Primary Hypercholesterolemia , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[28]  H. Ginsberg.  REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. , 2006, The Journal of clinical endocrinology and metabolism.

[29]  J. Kastelein,et al.  Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. , 2005, Journal of lipid research.

[30]  E. Harrison,et al.  Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. , 2005, The Journal of nutrition.

[31]  J. Repa,et al.  Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption Published, JLR Papers in Press, January 16, 2005. DOI 10.1194/jlr.M400475-JLR200 , 2005, Journal of Lipid Research.

[32]  Charles C Schwartz,et al.  Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.M300511-JLR200 , 2004, Journal of Lipid Research.

[33]  J. Kane,et al.  Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients With Sitosterolemia , 2004, Circulation.

[34]  D. Tribble,et al.  Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans , 2002, Circulation.

[35]  H. Davis,et al.  The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. , 2001, European journal of pharmacology.

[36]  J. Dietschy.  Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. , 1997, The American journal of clinical nutrition.

[37]  D. Schoeller,et al.  Measurement of fractional lipid synthesis using deuterated water (2H2O) and mass isotopomer analysis. , 1994, The American journal of physiology.

[38]  L. Zech,et al.  Cholesterol kinetics in subjects with bile fistula. Positive relationship between size of the bile acid precursor pool and bile acid synthetic rate. , 1993, The Journal of clinical investigation.

[39]  B. Lamarche,et al.  patient-oriented and epidemiological research Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia , 2009 .